The present technology relates to adjustable flow glaucoma shunts and methods for making and using such devices.
Glaucoma (e.g., ocular hypertension) is a disease associated with an increase in pressure within the eye resultant from an increase in production of aqueous humor (aqueous) within the eye and/or a decrease in the rate of outflow of aqueous from within the eye into the blood stream. Aqueous is produced in the ciliary body at the boundary of the posterior and anterior chambers of the eye. It flows into the anterior chamber and eventually into the capillary bed in the sclera of the eye. Glaucoma typically results from a failure in mechanisms that transport aqueous out of the eye and into the blood stream.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily drawn to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the component is necessarily transparent. Components may also be shown schematically.
The present technology is directed to adjustable flow glaucoma shunts and methods for making and using such devices. In many of the embodiments disclosed herein, the adjustable flow glaucoma shunts comprise an adjustable fluid resistor (“resistor” within the context of this document refers to a fluid resistor), actuator, and/or actuation mechanism. Additionally, in certain embodiments, the shunts may also include an adjustable opening pressure control mechanism. These mechanisms can be selectively adjusted or modulated to increase or decrease the outflow resistance and/or opening pressure of the shunt in response to changes in any (or any combination of) intraocular pressure (IOP), aqueous production rate, native aqueous outflow resistance, and/or native aqueous outflow rate.
In one embodiment, for example, a variable flow shunt for treating glaucoma in a human patient comprises an elongated outflow tube having (a) a proximal inflow portion configured for placement within an anterior chamber in a region outside of an optical field of view of an eye of the patient, and (b) a distal outflow portion at a different location of the eye. The variable flow shunt further includes a flow control mechanism positioned along the outflow tube between the inflow portion and the outflow portion. The flow control mechanism comprises one or more control elements transformable between an open position that allows fluid to flow through the outflow tube and resistance positions that partially obstruct or attenuate fluid flow through the outflow tube. During operation, the control element(s) are movable between positions in response to non-invasive energy.
In another embodiment of the present technology, a shunt for treatment of glaucoma in a human patient comprises an elongated outflow drainage tube having a proximal inflow region and a distal outflow region. The shunt also includes an inflow control assembly at the proximal inflow region, and a transition region along the outflow tube between the inflow region and the outflow region. During operation, the transition region is transformable between a first shape and a second shape different than the first shape to inhibit or attenuate fluid flow through the outflow tube.
A method for treating glaucoma in a human patient in accordance with still another embodiment of the present technology can include positioning a variable flow shunt within an eye of the patient. The shunt comprises an elongated outflow drainage tube having a proximal inflow region at a first portion of the eye and a distal outflow region at a second, different portion of the eye. The method also includes transforming a flow control assembly carried by the elongated outflow drainage tube from a first configuration to second, different configuration to selectively control flow of aqueous through the variable flow shunt. Throughout the method, the flow control assembly may be actuated via non-invasive energy.
Specific details of various embodiments of the present technology are described below with reference to
For ease of reference, throughout this disclosure identical reference numbers are used to identify similar or analogous components or features, but the use of the same reference number does not imply that the parts should be construed to be identical. Indeed, in many examples described herein, the identically numbered parts are distinct in structure and/or function.
Implantable Shunts for Glaucoma Treatment
Glaucoma is a degenerative ocular condition characterized by an increase in pressure within the eye resultant from an increase in production of aqueous humor (aqueous) within the eye and/or a decrease in the rate of outflow of aqueous from within the eye into the blood stream. The early stages of glaucoma are typically treated with drugs (e.g., eye drops). When drug treatments no longer suffice, however, surgical approaches may be used. Surgical or minimally invasive approaches primarily attempt to increase the outflow of aqueous from the anterior chamber to the blood stream either by the creation of alternative fluid paths or the augmentation of the natural paths for aqueous outflow.
Devices used to lower outflow resistance are generally referred to as “glaucoma shunts” or “shunts.”
Referring to
Outflow resistance changes over time as the outflow location goes through its healing process after surgical implantation of the device. Because the outflow resistance changes over time, in many procedures the shunt (e.g., shunts 100a-c) is modified at implantation to temporarily increase its outflow resistance. After a period of time deemed sufficient to allow for healing of the tissues and stabilization of the outflow resistance, the modification to the shunt is reversed, thereby decreasing the outflow resistance. Such modifications can be invasive, time-consuming, and expensive for patients. If such a procedure is not followed, however, the likelihood of creating hypotony and its resultant problems is high. Accordingly, the present technology provides variable flow glaucoma shunts that enable a user to remotely actuate a flow control mechanism to selectively alter the flow of fluid through the shunt. The selectively adjustable shunts may be similar in certain aspects to those described in PCT Patent Publication No. 2019/018807, titled “ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAME,” the disclosure of which is incorporated by reference herein in its entirety.
Selected Embodiments of Variable Flow Glaucoma Shunts
The shunt 300 further includes a flow control mechanism 310 positioned along the drainage tube 302 and configured to act as a variable resistor during operation and selectively control flow of fluid through the drainage tube 302. In the illustrated embodiment, for example, the flow control mechanism 310 comprises a body portion 311 slidably positioned along the drainage tube 302. In other embodiments, however, the flow control mechanism 310 may be carried by or engaged with the drainage tube 302 in a different arrangement. The flow control mechanism 310 includes one or more control elements 312 (two are shown in the illustrated embodiment as a first control element 312a and a second control element 312b). The flow control elements 312a-b are configured to be selectively activated by non-invasive energy (e.g., a surgical laser, light, heat, etc.) and, upon activation, pivotably move into the flow path through the drainage tube 302 to inhibit/attenuate flow therethrough. In various embodiments, flow is modified in some manner (e.g., pressure and/or flow) between the activated and non-activated configurations. In various embodiments, activation inhibits and/or attenuates flow through the drainage tube. One will appreciate from the description herein that activation may refer to selecting or moving between one of a variety of positions or configurations of the flow control mechanism. Further, in various embodiments, in the non-activated configuration, the drainage tube 302 is fully open. In various embodiments, in the activated configuration, the drainage tube is fully closed, thus preventing/inhibiting fluid flow through the drainage tube 302.
The first and second fingers 314 and 316 also each include target indicia or marker(s) 318 (“targets 318”). One or more individual targets 318 are included on each of the first and second fingers 314 and 316 and positioned as markers/targets for non-invasive energy used to selectively activate the flow control mechanism 310. The first and second fingers 314 and 316 are composed of a shape memory material (e.g., nitinol) and adapted to pivotably move when such non-invasive energy is applied. For example, applying heat to the first finger 314 (e.g., non-invasive energy applied to target(s) 318 on the first finger 314) can induce this feature to depress or move downward, thereby pushing the corresponding second finger 316 into the flow path (as best seen in
In the illustrated embodiment, the shunt 300 includes two flow control elements 312a and 312b positioned adjacent each other along the drainage tube 302. In other embodiments, however, the shunt 300 may include a different number of flow control elements 312 (e.g., a single flow control element 312 or greater than two flow control elements 312). Further, the individual flow control elements 312 may have a different arrangement relative to each other along the drainage tube 302.
When engaged with the drainage tube 302, the flow control mechanism 410 is configured to function in a similar fashion to the flow control mechanism 310 described above with reference to
In the illustrated embodiment, the flow control mechanism 410 of the shunt 400 includes three first flow control elements 412a and three second flow control elements 412b. In other embodiments, however, the shunt 400 may include a different number of flow control elements 412 and/or the individual flow control elements 412 may have a different arrangement relative to each other. In some embodiments, for example, the flow control elements 412 may be oriented in the opposite direction as that shown in
Each of the lumens 522 further comprises a flow control element 524. As best seen in
In some embodiments, the lumens 522 may each have the same flow resistance. In embodiments in which the lumens 522 have the same flow resistance, opening additional lumens 522 is expected to result in a generally linear increase in the drainage rate, and blocking lumens 522 is expected to result in a generally linear decrease in the drainage rate. For example, moving from a single open lumen to two open lumens is expected to generally double the drainage rate, while moving from two open lumens to three open lumens is expected to generally increase the drainage rate by 50 percent.
In other embodiments, however, the lumens 522 may have different flow resistances. Flow resistance through the lumens 522, and thus drainage rates through the lumens 522, can be varied based on, for example, a length of the lumen and/or a diameter of the lumen. The length of the lumen is generally proportional to the flow resistance of the lumen, whereas the diameter of the lumen is generally inversely proportional to the flow resistance of the lumen. Accordingly, each individual lumen 522 may have a unique length, diameter, or length and diameter combination that gives it a certain flow resistance. Individual channels can then be selectively opened (or closed) to achieve a desired flow rate.
As best seen in
In further embodiments, the inflow control assembly 610 of the shunt 600 may include one or more additional spring elements 630 positioned to be actuated to selectively control fluid flow. Further, in some embodiments the shunt 600 can include a thermal isolation element positioned between the individual springs to help further ensure that only one spring actuates at a time after delivery of non-invasive energy. The thermal isolation element(s) are an optional feature that may not be included in some embodiments.
In many of the embodiments described herein, the actuators or fluid resistors are configured to introduce features that selectively impede or attenuate fluid flow through the drainage tube during operation. In this way, the actuators/fluid resistors can incrementally or continuously change the flow resistance through the drainage tube to selectively regulate pressure/flow. The actuators and fluid resistors configured in accordance with the present technology can accordingly adjust the level of interference or compression between a number of different positions, and accommodate a multitude of variables (e.g., IOP, aqueous production rate, native aqueous outflow resistance, and/or native aqueous outflow rate) to precisely regulate flow rate through the drainage tube.
The disclosed actuators and fluid resistors can all be operated using non-invasive energy. This feature allows such devices to be implanted in the patient and then modified/adjusted over time without further invasive surgeries or procedures for the patient. Further, because the devices disclosed herein may be actuated via non-invasive energy, such devices do not require any additional power to maintain a desired orientation or position. Rather, the actuators/fluid resistors disclosed herein can maintain a desired position/orientation without power. This can significantly increase the usable lifetime of such devices and enable such devices to be effective long after the initial implantation procedure.
Several aspects of the present technology are set forth in the following examples.
1. A variable flow shunt for treatment of glaucoma in a human patient, the variable flow shunt comprising:
2. The variable flow shunt of example 1 wherein the one or more control elements are transformable between a first resistance position that provides a first level of reduction of fluid flow, and a second resistance position that provides a second level of reduction of fluid flow greater than the first level of reduction.
3. The variable flow shunt of example 1 wherein the one or more control elements are transformable between a first resistance position that provides a first level of flow reduction and a plurality of second resistance positions that provide increasing levels of flow reduction.
4. The variable flow shunt of example 1 or example 2 wherein the one or more control elements are configured to partially obstruct fluid flow through the outflow tube in the at least one resistance position by changing a diameter and/or a cross-sectional shape of a flow path through the outflow tube.
5. The variable flow shunt of any one of examples 1˜4 wherein the one or more control elements are movable between the open position and the at least one resistance position in response to laser energy.
6. The variable flow shunt of any one of examples 1-5 wherein the one or more control elements are configured to hold the open position or the at least one resistance position without power.
7. The variable flow shunt of example 1 wherein at least one control element comprises:
8. A shunt for treatment of glaucoma in a human patient, the shunt comprising:
9. The shunt of example 8 wherein the transition region is configured to transform between the first shape and the second shape upon application of non-invasive energy to one or more selected areas of the transition region.
10. The shunt of example 9 wherein the non-invasive energy is laser energy.
11. A method for treating glaucoma in a human patient, the method comprising:
12. The method of example 11 wherein transforming the flow control assembly carried by the elongated outflow drainage tube comprises actuating the flow control assembly, via the non-invasive energy, to pivotably move a control element of the control assembly into a flow path of the drainage tube such that flow along the flow path is attenuated.
13. The method of example 12, further comprising actuating the flow control assembly, via the non-invasive energy, to pivotably move the control element out of the flow path of the drainage tube such that flow along the flow path is returned to a non-attenuated state.
14. An adjustable flow shunt for treating glaucoma in a human patient, the shunt comprising:
15. The adjustable flow shunt of example 14 wherein the inflow control assembly is configured for placement within an anterior chamber in a region outside of the optical field of view of the eye.
16. The adjustable flow shunt of example 14 or example 15 wherein the spring element is configured to be activated via laser energy.
17. The adjustable flow shunt of any one of examples 14-16 wherein the spring element is composed of a shape memory material.
18. The adjustable flow shunt of any one of examples 14-16 wherein the spring element is composed of nitinol.
19. A variable fluid resistor shunt for treatment of glaucoma, the variable fluid resistor shunt comprising:
20. The variable fluid resistor shunt of example 19 wherein at least two of the multiple fluid lumens have a different flow resistance when the corresponding flow control element is in the first open position.
21. The variable fluid resistor shunt of example 19 or example 20 wherein the multiple fluid lumens include a first lumen and a second lumen, and wherein the first lumen has a first diameter and the second lumen has a second diameter greater than the first diameter.
22. The variable fluid resistor shunt of any of examples 19-21 wherein the multiple fluid lumens include a first lumen and a second lumen, and wherein the first lumen has a first length and the second lumen has a second length greater than the first length.
23. The variable fluid resistor shunt of example 19 wherein each of the multiple fluid lumens have the same flow resistance when the corresponding flow control element is in the first open position.
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, any of the features of the variable flow shunts described herein may be combined with any of the features of the other variable flow shunts described herein and vice versa. Moreover, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions associated with variable flow shunts have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application is a 35 U.S.C. § 371 U.S. National Phase application of International Patent Application No. PCT/US2020/014186, filed Jan. 17, 2020, which claims the benefit of U.S. Patent Application No. 62/794,430, filed Jan. 18, 2019, and titled “ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAME,” the disclosures of which are incorporated herein by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/014186 | 1/17/2020 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2020/150663 | 7/23/2020 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4401107 | Harber et al. | Aug 1983 | A |
4402681 | Haas et al. | Sep 1983 | A |
4595390 | Hakim et al. | Jun 1986 | A |
5070697 | Van Zeggeren | Dec 1991 | A |
5123906 | Kelman | Jun 1992 | A |
5300020 | L'Esperance, Jr. | Apr 1994 | A |
5476445 | Baerveldt et al. | Dec 1995 | A |
5601094 | Reiss | Feb 1997 | A |
5792118 | Kurth et al. | Aug 1998 | A |
6077298 | Tu et al. | Jun 2000 | A |
6077299 | Adelberg et al. | Jun 2000 | A |
6203513 | Yaron et al. | Mar 2001 | B1 |
6261256 | Ahmed | Jul 2001 | B1 |
6450984 | Lynch et al. | Sep 2002 | B1 |
6508779 | Suson | Jan 2003 | B1 |
6589203 | Mitrev | Jul 2003 | B1 |
6626858 | Lynch et al. | Sep 2003 | B2 |
6638239 | Bergheim | Oct 2003 | B1 |
6666841 | Gharib et al. | Dec 2003 | B2 |
6736791 | Tu et al. | May 2004 | B1 |
6789447 | Zinck | Sep 2004 | B1 |
7025740 | Ahmed | Apr 2006 | B2 |
7207965 | Simon | Apr 2007 | B2 |
7354416 | Quiroz-Mereado et al. | Apr 2008 | B2 |
7364564 | Sniegowski et al. | Apr 2008 | B2 |
7458953 | Peyman | Dec 2008 | B2 |
7699882 | Stamper et al. | Apr 2010 | B2 |
7717872 | Shetty | May 2010 | B2 |
7947008 | Grahn et al. | May 2011 | B2 |
8012134 | Claude et al. | Sep 2011 | B2 |
8206333 | Schmidt | Jun 2012 | B2 |
8206440 | Guarnieri | Jun 2012 | B2 |
8298240 | Giger et al. | Oct 2012 | B2 |
8308701 | Horvath et al. | Nov 2012 | B2 |
8414635 | Hyodoh et al. | Apr 2013 | B2 |
8506515 | Burns et al. | Aug 2013 | B2 |
8540659 | Berlin | Sep 2013 | B2 |
8579848 | Field et al. | Nov 2013 | B2 |
8585629 | Grabner et al. | Nov 2013 | B2 |
8663303 | Horvath et al. | Mar 2014 | B2 |
8702639 | Van Der Mooren | Apr 2014 | B2 |
8721702 | Romoda et al. | May 2014 | B2 |
8753305 | Field et al. | Jun 2014 | B2 |
8758290 | Horvath et al. | Jun 2014 | B2 |
8765210 | Romoda et al. | Jul 2014 | B2 |
8771220 | Nissan et al. | Jul 2014 | B2 |
8801766 | Reitsamer et al. | Aug 2014 | B2 |
8828070 | Romoda et al. | Sep 2014 | B2 |
8852136 | Horvath et al. | Oct 2014 | B2 |
8852137 | Horvath et al. | Oct 2014 | B2 |
8852256 | Horvath et al. | Oct 2014 | B2 |
8882781 | Smedley et al. | Nov 2014 | B2 |
8915877 | Cunningham et al. | Dec 2014 | B2 |
8932247 | Stergiopulos | Jan 2015 | B2 |
8974511 | Horvath et al. | Mar 2015 | B2 |
9017276 | Horvath et al. | Apr 2015 | B2 |
9095411 | Horvath et al. | Aug 2015 | B2 |
9095413 | Romoda et al. | Aug 2015 | B2 |
9113994 | Horvath et al. | Aug 2015 | B2 |
9125723 | Horvath et al. | Sep 2015 | B2 |
9192518 | Horvath et al. | Nov 2015 | B2 |
9226851 | Gunn | Jan 2016 | B2 |
9271869 | Horvath et al. | Mar 2016 | B2 |
9283115 | Lind | Mar 2016 | B2 |
9283116 | Romoda et al. | Mar 2016 | B2 |
9289324 | Johnson | Mar 2016 | B2 |
9326891 | Horvath et al. | May 2016 | B2 |
9375347 | Stergiopulos | Jun 2016 | B2 |
9393153 | Horvath et al. | Jul 2016 | B2 |
9555410 | Brammer et al. | Jan 2017 | B2 |
9585789 | Silvestrini et al. | Mar 2017 | B2 |
9585790 | Horvath et al. | Mar 2017 | B2 |
9592154 | Romoda et al. | Mar 2017 | B2 |
9610195 | Horvath | Apr 2017 | B2 |
9636254 | Yu et al. | May 2017 | B2 |
9636255 | Haffner et al. | May 2017 | B2 |
9655778 | Tyler | May 2017 | B2 |
9655779 | Bigler et al. | May 2017 | B2 |
9693900 | Gallardo Inzunza | Jul 2017 | B2 |
9693901 | Horvath et al. | Jul 2017 | B2 |
9757276 | Penhasi | Sep 2017 | B2 |
9808373 | Horvath et al. | Nov 2017 | B2 |
9877866 | Horvath et al. | Jan 2018 | B2 |
9883969 | Horvath et al. | Feb 2018 | B2 |
9980854 | Horvath et al. | May 2018 | B2 |
10004638 | Romoda et al. | Jun 2018 | B2 |
10080682 | Horvath et al. | Sep 2018 | B2 |
10085884 | Reitsamer et al. | Oct 2018 | B2 |
10154924 | Clauson et al. | Dec 2018 | B2 |
10159600 | Horvath et al. | Dec 2018 | B2 |
10195078 | Horvath et al. | Feb 2019 | B2 |
10195079 | Horvath et al. | Feb 2019 | B2 |
10231871 | Hill | Mar 2019 | B2 |
10238536 | Olson et al. | Mar 2019 | B2 |
10285853 | Man et al. | May 2019 | B2 |
10307293 | Horvath et al. | Jun 2019 | B2 |
10314743 | Romoda et al. | Jun 2019 | B2 |
10322267 | Hakim | Jun 2019 | B2 |
10369048 | Horvath et al. | Aug 2019 | B2 |
10405903 | Biesinger et al. | Sep 2019 | B1 |
10335030 | Alhourani | Oct 2019 | B2 |
10342703 | Siewert et al. | Nov 2019 | B2 |
10463537 | Horvath et al. | Nov 2019 | B2 |
10470927 | Horvath et al. | Nov 2019 | B2 |
10363168 | Schieber et al. | Dec 2019 | B2 |
10492948 | Baerveldt | Dec 2019 | B2 |
10524959 | Horvath | Jan 2020 | B2 |
10524958 | Camras et al. | Mar 2020 | B2 |
10596035 | Stergiopulos et al. | Apr 2020 | B2 |
10758412 | Velasquez | Apr 2020 | B2 |
10716663 | Salahieh et al. | Jul 2020 | B2 |
11122975 | Rodger et al. | Jan 2021 | B2 |
10912675 | Lubatschowski | Feb 2021 | B2 |
11166847 | Badawi et al. | Feb 2021 | B2 |
11166849 | Mixter et al. | Feb 2021 | B2 |
10952897 | Smith | Mar 2021 | B1 |
10960074 | Berdahl | Mar 2021 | B2 |
11007061 | Passman et al. | May 2021 | B2 |
11039954 | Cohen et al. | Jun 2021 | B2 |
11058581 | Mixter et al. | Jul 2021 | B2 |
11065154 | Sponsel et al. | Jul 2021 | B1 |
11083624 | Stein et al. | Aug 2021 | B2 |
11166848 | Mixter et al. | Nov 2021 | B2 |
11291585 | Schultz et al. | Apr 2022 | B2 |
11517477 | Lilly et al. | Dec 2022 | B2 |
11529258 | Chang et al. | Dec 2022 | B2 |
11596550 | Chang et al. | Mar 2023 | B2 |
11737920 | Chang et al. | Aug 2023 | B2 |
11766355 | Argento et al. | Sep 2023 | B2 |
11865283 | Schultz et al. | Jan 2024 | B2 |
12220350 | Mixter et al. | Feb 2025 | B2 |
12226343 | Mixter et al. | Feb 2025 | B2 |
20010011585 | Cassidy et al. | Aug 2001 | A1 |
20020177891 | Miles et al. | Nov 2002 | A1 |
20020193725 | Odrich | Dec 2002 | A1 |
20030079329 | Yaron et al. | May 2003 | A1 |
20030127090 | Gifford et al. | Jul 2003 | A1 |
20030163079 | Burnett | Aug 2003 | A1 |
20030183008 | Bang | Oct 2003 | A1 |
20040010219 | McCusker et al. | Jan 2004 | A1 |
20040162545 | Brown et al. | Aug 2004 | A1 |
20040190153 | Esch | Sep 2004 | A1 |
20040193095 | Shadduck | Sep 2004 | A1 |
20040254520 | Porteous et al. | Dec 2004 | A1 |
20050049578 | Tu et al. | Mar 2005 | A1 |
20050059956 | Varner et al. | Mar 2005 | A1 |
20050182350 | Nigam | Aug 2005 | A1 |
20050196424 | Chappa | Sep 2005 | A1 |
20060004317 | Mauge et al. | Jan 2006 | A1 |
20060069340 | Simon | Mar 2006 | A1 |
20060155300 | Stamper | Jul 2006 | A1 |
20060212113 | Shaolian et al. | Sep 2006 | A1 |
20060276739 | Brown | Dec 2006 | A1 |
20070010837 | Tanaka | Jan 2007 | A1 |
20070078371 | Brown et al. | Apr 2007 | A1 |
20070088432 | Solovay et al. | Apr 2007 | A1 |
20070265646 | McCoy et al. | Nov 2007 | A1 |
20070299487 | Shadduck | Dec 2007 | A1 |
20080077071 | Yaron et al. | Mar 2008 | A1 |
20080103440 | Ferren et al. | May 2008 | A1 |
20080119891 | Miles et al. | May 2008 | A1 |
20080125691 | Yaron et al. | May 2008 | A1 |
20080228127 | Burns et al. | Sep 2008 | A1 |
20080277332 | Liu | Nov 2008 | A1 |
20090012483 | Blott et al. | Jan 2009 | A1 |
20090036818 | Grahn et al. | Feb 2009 | A1 |
20090043321 | Conston et al. | Feb 2009 | A1 |
20090243956 | Keilman et al. | Oct 2009 | A1 |
20090259236 | Burnett et al. | Oct 2009 | A2 |
20090287136 | Castillejos | Nov 2009 | A1 |
20090314970 | McAvoy | Dec 2009 | A1 |
20090326432 | Schmidt et al. | Dec 2009 | A1 |
20090326517 | Bork et al. | Dec 2009 | A1 |
20100114006 | Baerveldt | May 2010 | A1 |
20100234791 | Lynch et al. | Sep 2010 | A1 |
20100241077 | Geipel et al. | Sep 2010 | A1 |
20100249691 | Van Der Mooren et al. | Sep 2010 | A1 |
20120035525 | Silvestrini | Feb 2012 | A1 |
20120065570 | Yeung et al. | Mar 2012 | A1 |
20120078220 | Fallin et al. | Mar 2012 | A1 |
20120089073 | Cunningham, Jr. | Apr 2012 | A1 |
20120232461 | Seaver et al. | Sep 2012 | A1 |
20130085440 | Bohm | Apr 2013 | A1 |
20130131577 | Bronstein et al. | May 2013 | A1 |
20130150773 | Nissan et al. | Jun 2013 | A1 |
20130150776 | Bohm et al. | Jun 2013 | A1 |
20130158381 | Rickard | Jun 2013 | A1 |
20130197621 | Ryan et al. | Aug 2013 | A1 |
20130199646 | Brammer et al. | Aug 2013 | A1 |
20130205923 | Brammer et al. | Aug 2013 | A1 |
20130211312 | Gelvin | Aug 2013 | A1 |
20130267887 | Kahook et al. | Oct 2013 | A1 |
20130317412 | Dacquay et al. | Nov 2013 | A1 |
20130338564 | Rickard et al. | Dec 2013 | A1 |
20140046439 | Dos Santos et al. | Feb 2014 | A1 |
20140081195 | Clauson et al. | Mar 2014 | A1 |
20140236068 | Van Der Mooren et al. | Aug 2014 | A1 |
20140309611 | Wilt et al. | Oct 2014 | A1 |
20150011926 | Reitsamer et al. | Jan 2015 | A1 |
20150034217 | Vad | Feb 2015 | A1 |
20150045716 | Gallardo Inzunza | Feb 2015 | A1 |
20150142049 | Delgado et al. | May 2015 | A1 |
20150230843 | Palmer et al. | Aug 2015 | A1 |
20150257931 | Sanchez | Sep 2015 | A1 |
20150265469 | Olson et al. | Sep 2015 | A1 |
20150313603 | Bodewadt et al. | Nov 2015 | A1 |
20160058615 | Camras et al. | Mar 2016 | A1 |
20160067093 | Johnson et al. | Mar 2016 | A1 |
20160151179 | Favier et al. | Jun 2016 | A1 |
20160220794 | Negre | Aug 2016 | A1 |
20160256317 | Horvath et al. | Sep 2016 | A1 |
20160256318 | Horvath et al. | Sep 2016 | A1 |
20160256319 | Horvath et al. | Sep 2016 | A1 |
20160287439 | Stergiopulos | Oct 2016 | A1 |
20160354244 | Horvath et al. | Dec 2016 | A1 |
20160354245 | Horvath et al. | Dec 2016 | A1 |
20170027582 | Khoury et al. | Feb 2017 | A1 |
20170071791 | Piven | Mar 2017 | A1 |
20170087016 | Camras | Mar 2017 | A1 |
20170017279 | Horvath et al. | Jun 2017 | A1 |
20170172798 | Horvath et al. | Jun 2017 | A1 |
20170172799 | Horvath | Jun 2017 | A1 |
20170312125 | Clauson et al. | Nov 2017 | A1 |
20170348149 | Stergiopulos et al. | Dec 2017 | A1 |
20170348150 | Horvath et al. | Dec 2017 | A1 |
20180014828 | Fonte et al. | Jan 2018 | A1 |
20180028361 | Haffner et al. | Feb 2018 | A1 |
20180028366 | Tout et al. | Feb 2018 | A1 |
20180092775 | de Juan, Jr. et al. | Apr 2018 | A1 |
20180147089 | Horvath et al. | May 2018 | A1 |
20180177633 | Haffner et al. | Jun 2018 | A1 |
20180206878 | Uspenski et al. | Jul 2018 | A1 |
20180250166 | Lubatschowski | Sep 2018 | A1 |
20180256320 | Millwee et al. | Sep 2018 | A1 |
20180333296 | Heitzmann et al. | Nov 2018 | A1 |
20190000673 | Field et al. | Jan 2019 | A1 |
20190021907 | Horvath et al. | Jan 2019 | A1 |
20190038462 | Vandiest | Feb 2019 | A1 |
20190038463 | Kasic | Feb 2019 | A1 |
20190046356 | Laroche | Feb 2019 | A1 |
20190060118 | Hill | Feb 2019 | A1 |
20190133826 | Horvath et al. | Mar 2019 | A1 |
20190121278 | Kawamura et al. | Apr 2019 | A1 |
20190142632 | Badawi et al. | May 2019 | A1 |
20190151079 | Zaldivar | May 2019 | A1 |
20190167475 | Horvath et al. | Jun 2019 | A1 |
20190240069 | Horvath et al. | Aug 2019 | A1 |
20190247231 | McClunan | Aug 2019 | A1 |
20190254873 | Camras et al. | Aug 2019 | A1 |
20190274881 | Romoda et al. | Sep 2019 | A1 |
20190274882 | Romoda et al. | Sep 2019 | A1 |
20190307608 | Lee et al. | Oct 2019 | A1 |
20190344057 | Cima et al. | Nov 2019 | A1 |
20190350758 | Horvath et al. | Nov 2019 | A1 |
20190353269 | Ossmer et al. | Nov 2019 | A1 |
20190358086 | Camras et al. | Nov 2019 | A1 |
20190374384 | Xie et al. | Dec 2019 | A1 |
20200069469 | Horvath et al. | Mar 2020 | A1 |
20200085620 | Euteneuer et al. | Mar 2020 | A1 |
20200121503 | Badawi et al. | Apr 2020 | A1 |
20200121504 | Stegmann et al. | Apr 2020 | A1 |
20200129332 | Van Der Mooren et al. | Apr 2020 | A1 |
20200170839 | Borrmann et al. | Jun 2020 | A1 |
20200179171 | Crimaldi et al. | Jun 2020 | A1 |
20200214891 | Bigler et al. | Jul 2020 | A1 |
20200229977 | Mixter et al. | Jul 2020 | A1 |
20200229980 | Horvath | Jul 2020 | A1 |
20200229981 | Mixter et al. | Jul 2020 | A1 |
20200229982 | Mixter et al. | Jul 2020 | A1 |
20200246188 | Horvath et al. | Aug 2020 | A1 |
20200253725 | Hadba et al. | Aug 2020 | A1 |
20200261271 | Horvath et al. | Aug 2020 | A1 |
20200276050 | Simons et al. | Sep 2020 | A1 |
20200306086 | Da Silva Curiel et al. | Oct 2020 | A1 |
20200345549 | Lu et al. | Nov 2020 | A1 |
20200376239 | Heilman et al. | Dec 2020 | A1 |
20210015665 | Hacker et al. | Jan 2021 | A1 |
20210030590 | Blanda et al. | Feb 2021 | A1 |
20210038158 | Haffner et al. | Feb 2021 | A1 |
20210069486 | Hakim | Mar 2021 | A1 |
20210106462 | Sherwood et al. | Apr 2021 | A1 |
20210128357 | de Juan, Jr. et al. | May 2021 | A1 |
20210137736 | Cavuto et al. | May 2021 | A1 |
20210137737 | Burns et al. | May 2021 | A1 |
20210161713 | Bouremel et al. | Jun 2021 | A1 |
20210196516 | Ianchulev | Jul 2021 | A1 |
20210205132 | Horvath et al. | Jul 2021 | A1 |
20210212858 | Tran et al. | Jul 2021 | A1 |
20210251806 | Schultz et al. | Aug 2021 | A1 |
20210282922 | Cohen-Tzemaeh et al. | Sep 2021 | A1 |
20210298948 | Haffner et al. | Sep 2021 | A1 |
20210315806 | Haffner | Oct 2021 | A1 |
20210330499 | Wardle et al. | Oct 2021 | A1 |
20220142818 | Chang et al. | May 2022 | A1 |
20220160545 | Mixter et al. | May 2022 | A1 |
20220160546 | Mixter et al. | May 2022 | A1 |
20220168146 | Badawi et al. | Jun 2022 | A1 |
20220202613 | Chang et al. | Jun 2022 | A1 |
20220203078 | May | Jun 2022 | A1 |
20220241565 | Nae et al. | Aug 2022 | A1 |
20220265974 | Saul et al. | Aug 2022 | A1 |
20220273491 | Brown | Sep 2022 | A1 |
20220339035 | Lilly et al. | Oct 2022 | A1 |
20220354695 | Badawi et al. | Nov 2022 | A1 |
20220387216 | Schultz et al. | Dec 2022 | A1 |
20220387217 | Argento et al. | Dec 2022 | A1 |
20230086856 | Chang et al. | Mar 2023 | A1 |
20230092196 | Argento et al. | Mar 2023 | A1 |
20230201544 | Schultz et al. | Jun 2023 | A1 |
20230233378 | Chang et al. | Jul 2023 | A1 |
20230240891 | Lilly et al. | Aug 2023 | A1 |
20230285192 | Chang et al. | Sep 2023 | A1 |
20240139029 | Chang et al. | May 2024 | A1 |
20240173169 | Schultz et al. | May 2024 | A1 |
20240277522 | Schultz et al. | Aug 2024 | A1 |
20240277523 | Schultz et al. | Aug 2024 | A1 |
20240325697 | Schultz et al. | Oct 2024 | A1 |
20240399122 | Bronez et al. | Dec 2024 | A1 |
20250010044 | Schultz et al. | Jan 2025 | A1 |
Number | Date | Country |
---|---|---|
2014200171 | Jan 2014 | AU |
2014201621 | Mar 2016 | AU |
2016201445 | Mar 2016 | AU |
2018200325 | Feb 2018 | AU |
2017274654 | Dec 2018 | AU |
2020201818 | Apr 2020 | AU |
2017439185 | May 2020 | AU |
2018412569 | Oct 2020 | AU |
112017025859 | Aug 2018 | BR |
112020008969 | Oct 2020 | BR |
2987953 | Dec 2016 | CA |
3067172 | Dec 2018 | CA |
3080713 | May 2019 | CA |
3093160 | Sep 2019 | CA |
101360523 | Feb 2009 | CN |
101965211 | Feb 2011 | CN |
103476371 | Dec 2013 | CN |
104490515 | Apr 2015 | CN |
106726124 | May 2017 | CN |
108743016 | Nov 2018 | CN |
11405875 | Jul 2020 | CN |
2020011460 | Nov 2020 | CO |
10217061 | Mar 2003 | DE |
102010015447 | Oct 2011 | DE |
102017124885 | Apr 2019 | DE |
102018112065 | Nov 2019 | DE |
102019204846 | Oct 2020 | DE |
1292256 | Mar 2003 | EP |
1380317 | Jan 2004 | EP |
1737531 | Jan 2007 | EP |
2552369 | Jan 2017 | EP |
3302381 | Apr 2018 | EP |
1765234 | Oct 2019 | EP |
2999430 | Nov 2019 | EP |
2677981 | Apr 2020 | EP |
3659495 | Jun 2020 | EP |
3518846 | Aug 2020 | EP |
3666236 | Aug 2020 | EP |
3687374 | Aug 2020 | EP |
3706653 | Sep 2020 | EP |
3730104 | Oct 2020 | EP |
3735947 | Nov 2020 | EP |
3773377 | Feb 2021 | EP |
3846747 | Jul 2021 | EP |
3846748 | Jul 2021 | EP |
3329884 | Aug 2021 | EP |
2389138 | Sep 2021 | EP |
3870120 | Sep 2021 | EP |
3313335 | Nov 2021 | EP |
2725550 | Sep 2019 | ES |
2602434 | Sep 2022 | GB |
1252748 | May 2019 | HK |
043303 | Aug 2019 | HU |
2001-523519 | Nov 2001 | JP |
2013505065 | Feb 2013 | JP |
5576427 | Aug 2014 | JP |
2017526504 | Sep 2017 | JP |
2018-501010 | Jan 2018 | JP |
2018519892 | Jul 2018 | JP |
2018130580 | Aug 2018 | JP |
2018529466 | Oct 2018 | JP |
2019517366 | Jun 2019 | JP |
201905934 | Dec 2019 | JP |
2020049361 | Apr 2020 | JP |
2018015684 | Feb 2018 | KR |
20190019966 | Feb 2019 | KR |
20200021551 | Feb 2020 | KR |
20200059305 | May 2020 | KR |
2640455 | Aug 2019 | PL |
2640455 | May 2019 | PT |
2687764 | May 2019 | RU |
2018142990 | Jun 2020 | RU |
11202008604 | Oct 2020 | SG |
201906873 | Jun 2019 | TR |
WO1992019294 | Nov 1992 | WO |
WO1996019249 | Jun 1996 | WO |
WO2004073564 | Sep 2004 | WO |
WO2004081613 | Sep 2004 | WO |
WO2007011302 | Jan 2007 | WO |
WO2007087061 | Aug 2007 | WO |
WO2009111645 | Sep 2009 | WO |
WO2010111528 | Sep 2010 | WO |
WO2011034740 | Mar 2011 | WO |
WO2012040380 | Mar 2012 | WO |
WO2012113450 | Aug 2012 | WO |
WO2014130574 | Aug 2014 | WO |
WO2016033270 | Mar 2016 | WO |
WO2016100500 | Jun 2016 | WO |
WO2016149425 | Sep 2016 | WO |
WO2016196841 | Dec 2016 | WO |
WO2017058656 | Apr 2017 | WO |
WO2018229766 | Dec 2018 | WO |
WO2019018807 | Jan 2019 | WO |
WO2019094004 | May 2019 | WO |
WO2019094004 | May 2019 | WO |
WO2019165053 | Aug 2019 | WO |
WO2019172940 | Sep 2019 | WO |
WO2020150663 | Jul 2020 | WO |
WO2020215068 | Oct 2020 | WO |
WO2020223491 | Nov 2020 | WO |
WO2020231993 | Nov 2020 | WO |
WO2020261184 | Dec 2020 | WO |
WO2021028703 | Feb 2021 | WO |
WO2021068078 | Apr 2021 | WO |
WO2021072315 | Apr 2021 | WO |
WO2021072317 | Apr 2021 | WO |
WO2021113730 | Jun 2021 | WO |
WO2021142255 | Jul 2021 | WO |
WO2021151007 | Jul 2021 | WO |
WO2021163566 | Aug 2021 | WO |
WO2021168130 | Aug 2021 | WO |
WO2021174298 | Sep 2021 | WO |
WO2021176332 | Sep 2021 | WO |
WO2021188952 | Sep 2021 | WO |
WO2021204312 | Oct 2021 | WO |
WO2021212007 | Oct 2021 | WO |
WO2021230887 | Nov 2021 | WO |
WO2022159723 | Jul 2022 | WO |
WO2022175681 | Aug 2022 | WO |
WO2022220861 | Oct 2022 | WO |
WO2023004067 | Jan 2023 | WO |
WO2023278452 | Jan 2023 | WO |
WO2023009366 | Feb 2023 | WO |
WO2023063961 | Apr 2023 | WO |
WO2023064491 | Apr 2023 | WO |
WO2023091307 | May 2023 | WO |
WO2023107486 | Jun 2023 | WO |
WO2023215461 | Nov 2023 | WO |
WO2024026397 | Feb 2024 | WO |
WO2024030949 | Feb 2024 | WO |
WO2024097723 | May 2024 | WO |
WO2024097743 | May 2024 | WO |
WO2024220861 | Oct 2024 | WO |
201708295 | May 2020 | ZA |
Entry |
---|
International Search Report and Written Opinion received for PCT Application No. PCT/US22/35324, filed on Jun. 28, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Nov. 22, 2022, 12 pages. |
Extended European Search Report received for EP Application No. 20741616.5, Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 5, 2022, 8 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/37747, filed on Jul. 20, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Dec. 6, 2022, 15 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/37917, filed on Jul. 21, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Dec. 15, 2022, 15 pages. |
Keulegan et al. “Pressure Losses for Fluid Flow in Curved Pipes,” Journal of Research of the National Bureau of Standards, vol. 18, Jan. 31, 1937 (Jan. 31, 1937), 26 pages. |
Olsen et al. “Human sclera: thickness and surface area,” American Journal of Ophthalmology, vol. 125, Issue. 2, https://pubmed.ncbi.nlm.nih.gov/9467451, Feb. 1, 1998 (Feb. 1, 1998), 1 page. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/048863, filed on Nov. 3, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Feb. 16, 2023, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US20/55144, filed on Oct. 9, 2020, Applicant: Shifamed Holdings, LLC, Date of Mailing: Feb. 1, 2021, 16 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US20/55141, filed on Oct. 9, 2020, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jan. 29, 2021, 11 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/14774, filed on Jan. 22, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: May 12, 2021, 10 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/17962, filed on Feb. 12, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jun. 7, 2021, 12 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/23238, filed on Mar. 19, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jul. 8, 2021, 10 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/18601, filed on Feb. 18, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jul. 19, 2021, 12 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/27742, filed on Apr. 16, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 7, 2021, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US18/43158, filed on Jul. 20, 2018, Applicant: Shifamed Holdings, LLC, Date of Mailing: Nov. 23, 2018, 12 pages. |
International Search Reportand Written Opinion received for PCT Application No. PCT/US20/41159, filed on Jul. 8, 2020, Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 28, 2020, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US20/41152, filed on Jul. 8, 2020, Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 28, 2020, 13 pages. |
International Search Reportand Written Opinion received for PCT Application No. PCT/US20/14186, filed on Jan. 17, 2020, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jun. 4, 2020, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/49140, filed on Sep. 3, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: Dec. 7, 2021, 22 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/55258, filed on Oct. 15, 2021, Applicant: Shifamed Holdings, LLC, Date of Mailing: Feb. 28, 2022, 18 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/13336, filed on Jan. 21, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Apr. 11, 2022, 9 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/52002, filed on Dec. 6, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Mar. 21, 2023, 11 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/46604, filed on Oct. 13, 2022, Applicant: Shifamed Holdings, LLC, Date of Mailing: Mar. 30, 2023, 11 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US23/80290, filed on Nov. 17, 2023, Applicant: Shifamed Holdings, LLC, Date of Mailing: May 15, 2024, 12 pages. |
English translation of Japanese Office Action received for Application No. 2022-521301, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jun. 3, 2024, 3 pages. |
Extended European Search Report received for EP Application No. 23158246.1, Applicant: Shifamed Holdings, LLC, Date of Mailing: Aug. 7, 2023, 7 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US23/20973, filed on May 4, 2023, Applicant: Shifamed Holdings, LLC, Date of Mailing: Sep. 21, 2023, 15 pages. |
Extended European Search Report received for EP Application No. 20874212.2, Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 18, 2023, 8 pages. |
Extended European Search Report received for EP Application No. 20875070.3, Applicant: Shifamed Holdings, LLC, Date of Mailing: Dec. 19, 2023, 7 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US23/71501, filed on Aug. 2, 2023, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jan. 18, 2024, 20 pages. |
Extended European Search Report received for EP Application No. 21744394.4, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jan. 26, 2024, 7 pages. |
Extended European Search Report received for EP Application No. 21787751.3; Applicant: Shifamed Holdings, LLC, Date of Mailing: Mar. 15, 2024, 8 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US23/71116, filed on Jul. 27, 2023, Applicant: Shifamed Holdings, LLC, Date of Mailing: Mar. 1, 2024, 12 pages. |
Extended European Search Report received for EP Application No. 22743262.2; Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 28, 2024, 8 pages. |
Collins Dictionary, Textured definition and meaning, 2024, Collins Dictionary, https://www.collinsdictionary.com/dictionary/english/textured, Year: 2024, 1 page. |
English translation of Chinese Office Action received for CN Application No. 201880060989.1; Applicant: Shifamed Holdings, LLC, Date of Mailing: Oct. 18, 2024, 9 pages. |
English translation of Japanese Office Action received for Application No. 2022-521302; Applicant: Shifamed Holdings, LLC, Date of Mailing: Dec. 24, 2024, 7 pages. |
Extended European Search Report received for EP Application No. 21937177.0, Applicant: Shifamed Holdings, LLC, Date of Mailing: Jan. 16, 2025, 6 pages. |
Number | Date | Country | |
---|---|---|---|
20220087865 A1 | Mar 2022 | US |
Number | Date | Country | |
---|---|---|---|
62794430 | Jan 2019 | US |